Autolus Therapeutics plc (AUTL) Operating Margin
- Operating margin · 12 months: Value -210.78%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -210.78% | Operating income / revenue. Period ending 2026-06-30. $-247.44M ÷ $117.39M × 100 ≈ -210.78% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -247.44M USD | Operating Income (Loss) |
| Revenue | 117.39M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 99.01M USD | Cost of Goods and Services Sold |
| Research and development | 112.63M USD | Research and Development Expense |
| Selling, general and administration | 153.19M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-247.44M | $117.39M | $99.01M | $112.63M | $153.19M | -210.78% |
| 2026-03-31 | $-264.82M | $92.62M | $102.99M | $112.17M | $142.29M | -285.91% |
| 2025-12-31 | $-270.54M | $75.39M | $96.37M | $117.69M | $131.87M | -358.87% |
| 2025-09-30 | $-273.94M | $51.13M | $82.43M | $112.89M | $129.75M | -535.80% |
| 2025-06-30 | $-270.20M | $29.93M | $53.78M | $125.32M | $120.81M | -902.64% |
| 2025-03-31 | $-267.91M | $9.01M | $29.34M | $134.50M | $112.44M | -2973.13% |
| 2024-12-31 | $-241.43M | $10.12M | $11.39M | $138.44M | $101.09M | -2385.63% |
| 2024-09-30 | $-218.83M | (m) | (m) | $145.15M | (m) | (m) |
| 2024-06-30 | $-193.86M | (m) | (m) | $137.14M | (m) | (m) |
| 2024-03-31 | $-179.31M | (m) | (m) | $133.76M | (m) | (m) |
| 2023-12-31 | $-179.70M | (m) | (m) | $130.48M | (m) | (m) |
| 2023-09-30 | $-175.10M | (m) | (m) | $137.51M | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-146.37M | (m) | (m) | $116.38M | (m) | (m) |
| 2022-12-31 | $-168.05M | (m) | (m) | $141.99M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-137.36M | (m) | (m) | $108.47M | (m) | (m) |
| 2021-12-31 | $-165.00M | (m) | (m) | $134.79M | (m) | (m) |
| 2021-03-31 | $-169.45M | (m) | (m) | $134.33M | (m) | (m) |
| 2020-12-31 | $-168.15M | (m) | (m) | $134.89M | (m) | (m) |
| 2020-09-30 | $-163.90M | (m) | (m) | $125.53M | (m) | (m) |
| 2020-06-30 | $-156.81M | $1.24M | (m) | $119.30M | (m) | -12676.56% |
| 2020-03-31 | $-154.47M | $1.28M | (m) | $114.14M | (m) | -12049.14% |
| 2019-12-31 | $-146.06M | $2.91M | (m) | $105.42M | (m) | -5022.83% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.01M | (m) | $59.24M | (m) | (m) |
| 2018-12-31 | (m) | $1.47M | (m) | $48.30M | (m) | (m) |
| 2018-09-30 | (m) | $1.41M | (m) | $36.15M | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $1.69M | (m) | $16.01M | (m) | (m) |
| 2016-09-30 | (m) | $1.21M | (m) | $10.44M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |